AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11566047
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg GHRH administered as a single intravenous bolus
Trial: 11566047
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg GHRH administered as five repetitive boluses within 1 h
Trial: 9740479
Drug: Clonidine (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (transdermal patch)
Trial: 8092427
Drug: Amoxicillin (AX)
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (AX)
Trial: 8092427
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G (PG)
Trial: 3345614
Drug: Placebo gels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gels (various pH levels)
Trial: 30177674
Drug: Spinal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal ropivacaine (7-15 mg) in Group S (BMI <25)
Trial: 30177674
Drug: Spinal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal ropivacaine (7-15 mg) in Group M (25 ≤ BMI <30)
Trial: 30177674
Drug: Spinal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal ropivacaine (7-15 mg) in Group L (BMI ≥30)
Trial: 27102553
Drug: EPO +
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO + TXA (10,000 IU EPO daily subcutaneous injections on preoperative days 1-4 and postoperative days 1-3; 15 mg/kg TXA 10 min prior to incision)
Trial: 27102553
Drug: TXA (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA (15 mg/kg TXA 10 min prior to incision)
Trial: 26423182
Drug: Aripiprazole (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (target dose 10 mg [maximum 15 mg] daily) for 12 weeks
Trial: 2744633
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 500 mg
Trial: 2744633
Drug: Choline magnesium
RxNorm normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline magnesium trisalicylate (CMT) 500 mg
Trial: 736748
Drug: Predicted cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predicted cancer chemotherapy
Trial: 736748
Drug: Non-predicted or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-predicted or no surgical adjuvant chemotherapy
Trial: 29189311
Drug: Gabapentin 400
RxNorm normalized name: gabapentin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 400 mg
Trial: 29943522
Drug: Gabapentin 800
RxNorm normalized name: gabapentin 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 800 mg
Trial: 29189311
Drug: Gabapentin 400
RxNorm normalized name: gabapentin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 400 mg, 800 mg, 1200 mg
Trial: 25958769
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus brief self-hypnosis training (two × 90-minute groups at around 32 and 35 weeks' gestation; daily audio self-hypnosis CD)
Trial: 20652703
Drug: Tanespimycin suspension
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanespimycin suspension for injection
Trial: 20652703
Drug: Tanespimycin injection
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanespimycin injection (Cremophor-based formulation)
Trial: 20652703
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with tanespimycin (both formulations)
Trial: 17076973
Drug: Mebendazole 200
RxNorm normalized name: mebendazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 200 mg three times for 1 day
Trial: 17076973
Drug: Tinidazole 50
RxNorm normalized name: tinidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 50 mg/kg in a single dose
Trial: 11718213
Drug: GM-CSF for
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF for 3 days, five days prior to chemotherapy
Trial: 9109740
Drug: Physostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (30 mg transdermal patch, releasing about 6 mg over 24 hours)
Trial: 7959241
Drug: ESWL with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESWL with adjuvant bile acid treatment
Trial: 7959241
Drug: Bile salt
RxNorm normalized name: Bile salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bile salt treatment
Trial: 24850228
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (LAI) 45-405 mg every 2-4 weeks
Trial: 22408034
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg twice daily for 3 months)
Trial: 16509835
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg each morning)
Trial: 12623986
Drug: Calcineurin inhibitor-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitor-free regimen
Trial: 8198628
Drug: Nylestriol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nylestriol 2 mg/2 wk
Trial: 8198628
Drug: Nylestriol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nylestriol 1 mg/2 wk
Trial: 3085844
Drug: Supine position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine position with bumetanide 1 mg intravenously
Trial: 3085844
Drug: Upright position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upright position with bumetanide 1 mg intravenously
Trial: 31906925
Drug: Oral information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral information session
Trial: 31906925
Drug: Pamphlet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamphlet and oral information session
Trial: 24905063
Drug: Estradiol and
RxNorm normalized name: Estradiol and Norgestimate Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol and progestin therapy
Trial: 24905063
Drug: Estradiol, progestin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol, progestin, and testosterone therapy
Trial: 22395196
Drug: Nesiritide group
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide group (received conventional treatment plus nesiritide infusion at 0.0075-0.015 μg·kg(‐1)·min(‐1) for 10-15 hours, total 0.5-1.0 mg once daily for 13 days)
Trial: 22395196
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received only conventional treatment for AHF)
Trial: 20089489
Drug: Losartan 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 0.7 to 1.4 mg/kg per day
Trial: 20089489
Drug: Amlodipine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 0.1 to 0.2 mg/kg per day up to 5 mg/d
Trial: 10363572
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin (1.8 or 3.6 g/day)
Trial: 7727768
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination (ZDV 150 mg and ddl 134 mg, daily)
Trial: 7727768
Drug: Moderate-dose combination
RxNorm normalized name: Corticosteroids, moderately potent, other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose combination (ZDV 300 mg and ddl 334 mg, daily)
Trial: 7727768
Drug: High-dose combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose combination (ZDV 600 mg and ddl 500 mg, daily)
Trial: 7727768
Drug: ddl monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddl monotherapy (ddl 500 mg, daily)
Trial: 7727768
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms combined
Trial: 2201495
Drug: Max EPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Max EPA fish oil supplement (15 capsules/day with meals)
Trial: 17188087
Drug: 2.5% talactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% talactoferrin gel
Trial: 17188087
Drug: 8.5% talactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.5% talactoferrin gel
Trial: 15536575
Drug: Study solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study solution (2 mg of morphine, 15 mg of bupivacaine, 80 mg of methylprednisolone, and 0.05 mg of adrenaline)
Trial: 10767223
Drug: Montelukast alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast alone, 10 mg (ML(10))
Trial: 10767223
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol alone, 50 microg (SM(50))
Trial: 10767223
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg) and salmeterol (50 microg)
Trial: 10767223
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg) and inhaled salmeterol, 100 microg (SM(100))
Trial: 10767223
Drug: Placebo inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler and tablet
Trial: 10767223
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies vs ML(10) alone
Trial: 2942886
Drug: PCNG (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCNG (30 mg applied 30 minutes before induction)
Trial: 31697801
Drug: Emicizumab 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 1.5 mg/kg weekly (group A)
Trial: 31697801
Drug: Emicizumab 3
RxNorm normalized name: Emicizumab 30 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 3 mg/kg every 2 weeks (group B)
Trial: 31697801
Drug: Emicizumab 6
RxNorm normalized name: EMICIZUMAB 60 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Hemlibra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 6 mg/kg every 4 weeks (group C)
Trial: 28148685
Drug: Relative iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative iron bioavailability from 57FePP+ZnSO4
Trial: 28148685
Drug: Relative iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative iron bioavailability from 57FePP-Zn
Trial: 28148685
Drug: Relative iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative iron bioavailability from 57FePP+ZnO
Trial: 25856686
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg subcutaneously every 12 hours
Trial: 25856686
Drug: Enoxaparin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1.5 mg/kg subcutaneously every 24 hours
Trial: 10485504
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg/d
Trial: 11519776
Drug: rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg/d
Trial: 11519776
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg/d
Trial: 9710365
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg for 3 months
Trial: 7986182
Drug: Subcutaneously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered sumatriptan succinate
Trial: 7986182
Drug: Second injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second injection of subcutaneously administered sumatriptan succinate
Trial: 31900579
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg/day for 20 days)
Trial: 28898870
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 buccal spray 800 IU/daily
Trial: 28898870
Drug: Oral drops
RxNorm normalized name: Oral Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drops 750 IU/daily
Trial: 26347918
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further invasive treatment after primary PCI of the infarct-related artery only
Trial: 23832582
Drug: GSK1995057 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1995057 intravenous infusion (0.0004, 0.002, and 0.01 mg/kg)
Trial: 23832582
Drug: GSK1995057 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1995057 intravenous infusion
Trial: 17074624
Drug: Single steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single steroid injection
Trial: 14872153
Drug: Genomic medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomic medicine and candidate single nucleotide polymorphisms
Trial: 11696141
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl by bolus technique (Group 1, n=8)
Trial: 11696141
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl by continuous infusion (Group 2, n=6)
Trial: 11696141
Drug: Fentanyl-midazolam infusion
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl-midazolam infusion (Group 3, n=5)
Trial: 9140018
Drug: S-20098 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-20098 (5 mg)
Trial: 9140018
Drug: S-20098 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-20098 (100 mg)
Trial: 31540747
Drug: Treatment planning
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment planning designs based on MA.20, EORTC, AMAROS and Z0011 trials
Trial: 31540747
Drug: None of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None of the treatment plan designs
Trial: 31383427
Drug: No-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment group (control group)
Trial: 28575729
Drug: Saxagliptin 5mg
RxNorm normalized name: Saxagliptin 5mg Oral tablet
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5mg daily (S5 group)
Trial: 28575729
Drug: Metformin 1500mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1500mg daily (Met group)
Trial: 24649781
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine (10 ml bolus)
Trial: 14649215
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy as an adjunct treatment for cardiovascular disease
Trial: 14649215
Drug: Improved hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Improved hormone formulations and selective estrogen receptor modulators
Trial: 14649215
Drug: Understanding of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Understanding of estrogen receptors in vascular tissue
Trial: 14649215
Drug: Timing and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing and dosing for therapeutic intervention
Trial: 10397660
Drug: High-dose fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fluticasone propionate (100 microg per nostril) 4 times daily for 6 days
Trial: 7746690
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral poliovirus vaccine (3 doses at 2, 3, and 4 months)
Trial: 7746690
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral poliovirus vaccine (2 doses with shorter interval)
Trial: 1772001
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dipyridamole 75 mg t.i.d and acetylsalicylic acid 330 mg t.i.d.
Trial: 7042360
Drug: Indoprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoprofen (200 mg t.i.d.)
Trial: 28652278
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg/day orally, 3 weeks on, 1 week off) + Fulvestrant (500 mg) + Goserelin
Trial: 28652278
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Fulvestrant (500 mg) + Goserelin
Trial: 23135760
Drug: ITF prebiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF prebiotics (inulin/oligofructose 50/50 mix; 16 g/day for 3 months)
Trial: 22112039
Drug: HEMA-free one-step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HEMA-free one-step adhesive G-Bond (GC)
Trial: 17973945
Drug: simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin (40 mg/day)
Trial: 18072016
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of ezetimibe and simvastatin
Trial: 16025262
Drug: Amifostine 740
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine 740 mg/m2
Trial: 9092413
Drug: Specific inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific inhibitors (integrelin, lamifiban, tirofiban)
Trial: 1788581
Drug: Droperidol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.25 mg
Trial: 6119998
Drug: Neostigmine (0.011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.011 mg kg‐1)
Trial: 6119998
Drug: Neostigmine (0.010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.010 mg kg‐1)
Trial: 26452447
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once-daily
Trial: 19686113
Drug: 0.5% (w/w)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% (w/w) monosodium L-glutamate (MSG) added to rice gruel, 3 times a day for 3 months
Trial: 19686113
Drug: 0.5% (w/w)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% (w/w) monosodium L-glutamate (MSG)
Trial: 7895928
Drug: Omeprazole (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (8 mg/h after a bolus of 80 mg)
Trial: 7895928
Drug: Omeprazole (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (4 mg/h after a bolus of 80 mg)
Trial: 7895928
Drug: Ranitidine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (0.25 mg/kg/h after a bolus of 50 mg)
Trial: 31582549
Drug: No Granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Granulocyte colony-stimulating factor (non-G-CSF)
Trial: 17212913
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (laminectomy)
Trial: 31434781
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (structured physical training programme)
Trial: 23220856
Drug: Remifentanil dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil dosage adjusted according to SPI
Trial: 21669894
Drug: Sucrose plus
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose plus EMLA cream (S+E group)
Trial: 21669894
Drug: Sucrose plus
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose plus placebo cream (S group)
Trial: 3956275
Drug: Cimetidine (H2-antagonist)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (H2-antagonist)
Trial: 31490861
Drug: Early self-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early self-directed home exercise program (HEP) for 6 weeks with weekly supportive telephone calls
Trial: 29717497
Drug: Neutral agent
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral agent
Trial: 27684290
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg oral dose
Trial: 24515927
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (n = 14)
Trial: 18314230
Drug: Diacylglycerol oil
RxNorm normalized name: DIACYLGLYCEROL OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacylglycerol oil (25 g/day for 120 days)